• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 13.62
  • VXN 16.44
  • VXO 14.46
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





Company Profile

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic iron compounds to treat iron deficiency anemia (IDA) in the United States, Europe, and Japan. It also provides novel imaging agents to aid in the diagnosis of cancer and cardiovascular diseases. It offers Feraheme, an iron replacement therapeutic for the treatment of IDA in adult patients with chronic kidney disease; and GastroMARK used for delineating the bowel in magnetic resonance imaging (MRI). The company is also developing Feraheme, which is in Phase II clinical trials for use as a vascular-enhanced MRI agent for the assessment of peripheral arterial disease. AMAG Pharmaceuticals has collaborative agreements with 3SBio Inc. for the development and commercialization of Feraheme as an IV iron replacement therapeutic agent in China; Guerbet S.A; Takeda Pharmaceutical Co. Ltd.; and Covidien for marketing GastroMARK in the United States, Canada, and Mexico. The company was founded in 1981 and is based in Lexington, Massachusetts.

NO
     
AMAG (AMAG Pharmaceuticals Inc)
Last Trade 11.07 Date 12/7/2019
Change % 3.37 % Price Change 0.36
Open 10.8 52 Week High 18.39
High 11.18 52 Week Low 6.81
Low 10.7 Type stock
Volume 491041 Average Volume 791052
Prev Close 10.71 Stock Exchange NASDAQ
Bid 9.0 Ask 11.25
Bid Size 2 Ask Size 5
1st Yr Estimated EPS Growth -0.761 2nd Yr Estimated EPS Growth 1.0667
2 Years Forward Earning Yield -0.224 2 Years Forward PE Ratio
2 Years EV/Forward EBIT -7.6637 2 Years EV/Forward EBITDA
Book Value per Share 14.1712 Book Value Yield 1.2801
Buy Back Yield 0.0366 CAPE Ratio
Cash Return -0.3741 Cash Flow per Share -3.7979
Cash Flow Yield -0.3431 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.7606 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT -46.0452 EV / Forward EBITDA
EV / Forward Revenue 1.3261 EV / Pre Tax Income
EV / Revenue 1.4237 EV / Total Asset 0.4804
Expected Dividend Growth Rate Free Cash Flow per Share -5.6327
Free Caash Flow Ratio Free Cash Flow Yield -0.5088
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.1084 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 0.78116 PB Ratio 10 Year Growth -0.156419
PB Ratio 3 Year Growth 0.784557 Cash Ratio 3 Year Average 154.6258
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average 29.11032 PE Ratio 10 Year Growth
PE Ratio 10 Year High 86.5625 PE Ratio 10 Year Low 3.28725
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg 66.365015
PE Ratio 5 Year Avg 29.11032 PE Ratio 5 Year High 86.5625
PE Ratio 5 Year Low 3.28725 Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg 6.290228 Price Change 1 Month 1.039437
Price to Cash Ratio 1.960111 Price / EBITDA
Price to Sales Ratio 1.160179 Price to Sales Ratio 10 Year Growth -0.381776
Price to Sales Ratio 3 Year Avg 1.129336 Price to Sales Ratio 5 Year Avg 29.11032
Sale per Share 9.5416 Sales Yield 0.8619
Sustainable Growth Rate -0.4647 Tangible Book Value per Share -3.8172
Tangible Book Value per Share 3 year Avg -12.8998 Tangible Book Value per Share 5 year Avg -11.6799
Total Asset per Share 28.5003 Total Yield 0.0366
Working Capital per Share 4.0325 Working Capital per Share 3 Year Avg 9.389
Working Capital per Share 5 Year Avg 10.9034 Beta 0.00932